Glaxosmithkline Pharmaceuticals
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
GlaxoSmithKline Pharmaceuticals is strategically pivoting towards an innovation-led growth model, with management emphasizing oncology, respiratory, and adult vaccines as key growth pillars. This shift is expected to drive a 14% revenue CAGR through FY28, supported by increased marketing investments and field force expansion. However, the company faces regulatory challenges due to significant exposure to the National List of Essential Medicines (NLEM), which could pressure margins. Vista's financial outlook reflects an expectation of accelerating revenue growth beyond historical trends, with stable margins anticipated despite rising operational costs. The favorable macro environment, including currency depreciation, enhances export potential, benefiting the pharmaceutical sector. Over the next 12-24 months, key opportunities include the successful launch of innovative therapies and expansion into adult immunization, while watchpoints include execution risks related to supply constraints and competitive pressures from the loss of exclusivity for established products. Overall, the outlook remains cautiously optimistic, with a focus on disciplined execution and strategic investments in high-margin products
Why We Like This Stock
- Management's focus on oncology and adult vaccines is expected to significantly contribute to revenue growth
- The anticipated 14% revenue CAGR through FY28 reflects strong growth potential driven by innovative product launches
- Favorable currency dynamics are likely to enhance export opportunities, supporting overall revenue growth
Things To Watch Out For
- Regulatory headwinds from NLEM exposure could pressure margins and impact profitability
- Execution risks related to supply constraints may hinder sales growth in the short term
- The loss of exclusivity for key products like Infanrix Hexa could introduce competitive pressures in established segments
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 3,454 | 3,749 | 3,822 | 4,106 | 4,474 |
| Profit Before Tax (Cr.) | 910 | 1,187 | 1,385 | 1,512 | 1,652 |
| PBT Margin | 26.3% | 31.7% | 3623.8% | 36.8% | 36.9% |
| Net Profit (Cr.) | 646 | 880 | 1,030 | 1,129 | 1,234 |
| Earnings Per Share | 38.1 | 52.0 | 60.8 | 66.7 | 72.8 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Motilal Oswal | ► Neutral | 2,870 | 05-Aug-2026 |
Company Overview
Show Company Profile
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide. In addition, the company offers general medicines, including Augmentin, an oral antibiotic for respiratory tract infections, surgical prophylaxis, dental infections, and skin infections; Ceftum, an anti-infective medicine; Calpol and Calpol T for pain management; Eltroxin for the treatment of hypothyroidism; Neosporin, Betnovate, T-bact, Physiogel, Tenovate, and Flutivate for dermatology indications; and CobadexCZS and CCM, which are mineral, vitamins, and nutrition products. Further, it provides oncology medicines, including Jemperli and Zejula. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is headquartered in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.